STRIDES PHARMA SCIENCE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 876.7 INR | -0.76% |
|
+3.94% | +35.03% |
| Apr. 09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
| Jan. 30 | Transcript : Strides Pharma Science Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 42,303 | 28,854 | 75,754 | 31,121 | 25,858 | 80,568 | - | - |
| Enterprise Value (EV) 1 | 64,938 | 43,620 | 92,026 | 31,121 | 25,858 | 80,568 | 80,568 | 80,568 |
| P/E ratio | 13 x | 79.3 x | 28.2 x | -6.76 x | -12.7 x | -191 x | 21.6 x | 15.2 x |
| Yield | 0.64% | 4.35% | 0.3% | - | 0.52% | 0.41% | 0.41% | 0.41% |
| Capitalization / Revenue | 1.4 x | 1.05 x | 2.28 x | 1.01 x | 0.7 x | 1.96 x | 1.79 x | 1.62 x |
| EV / Revenue | 1.4 x | 1.05 x | 2.28 x | 1.01 x | 0.7 x | 1.96 x | 1.79 x | 1.62 x |
| EV / EBITDA | 9.3 x | 5.4 x | 12.1 x | -302 x | 6.01 x | 10.9 x | 10.1 x | 8.76 x |
| EV / FCF | -15.7 x | 52.6 x | 41.2 x | -7.76 x | -51.2 x | 14.6 x | 11.1 x | 8.95 x |
| FCF Yield | -6.36% | 1.9% | 2.43% | -12.9% | -1.95% | 6.83% | 9.01% | 11.2% |
| Price to Book | 1.6 x | 1.14 x | 2.89 x | 1.32 x | 1.19 x | 3.62 x | 3.22 x | 2.87 x |
| Nbr of stocks (in thousands) | 89,549 | 89,565 | 89,681 | 89,790 | 90,303 | 91,900 | - | - |
| Reference price 2 | 472.4 | 322.2 | 844.7 | 346.6 | 286.4 | 876.7 | 876.7 | 876.7 |
| Announcement Date | 5/10/19 | 5/20/20 | 5/27/21 | 5/24/22 | 5/25/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 30,117 | 27,520 | 33,159 | 30,702 | 36,884 | 41,139 | 45,135 | 49,619 |
| EBITDA 1 | 4,548 | 5,347 | 6,268 | -103.2 | 4,302 | 7,366 | 7,947 | 9,193 |
| EBIT 1 | 2,829 | 3,610 | 4,205 | -2,531 | 1,869 | 5,234 | 4,514 | 5,108 |
| Operating Margin | 9.39% | 13.12% | 12.68% | -8.24% | 5.07% | 12.72% | 10% | 10.29% |
| Earnings before Tax (EBT) | 1,204 | 1,619 | 3,733 | -5,417 | -2,862 | - | 4,430 | 6,044 |
| Net income 1 | 3,246 | 363.8 | 2,684 | -4,602 | -2,026 | -413.5 | 2,921 | 4,070 |
| Net margin | 10.78% | 1.32% | 8.1% | -14.99% | -5.49% | -1.01% | 6.47% | 8.2% |
| EPS 2 | 36.24 | 4.060 | 29.92 | -51.28 | -22.49 | -4.600 | 40.55 | 57.75 |
| Free Cash Flow 1 | -2,690 | 548.1 | 1,840 | -4,012 | -505.3 | 5,502 | 7,262 | 9,000 |
| FCF margin | -8.93% | 1.99% | 5.55% | -13.07% | -1.37% | 13.38% | 16.09% | 18.14% |
| FCF Conversion (EBITDA) | - | 10.25% | 29.35% | - | - | 74.7% | 91.38% | 97.9% |
| FCF Conversion (Net income) | - | 150.66% | 68.53% | - | - | - | 248.61% | 221.12% |
| Dividend per Share 2 | 3.000 | 14.00 | 2.500 | - | 1.500 | 3.600 | 3.600 | 3.600 |
| Announcement Date | 5/10/19 | 5/20/20 | 5/27/21 | 5/24/22 | 5/25/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,320 | 9,085 | 6,884 | 7,215 | 7,944 | 8,660 | 9,401 | 8,971 | 8,648 | 9,864 | 9,300 | 9,833 | 10,216 | 10,799 |
| EBITDA 1 | 1,661 | 1,592 | -553.5 | -10.78 | 46.05 | 415 | 601.5 | 981.3 | 1,163 | 1,556 | 1,666 | 1,792 | 2,096 | 1,951 |
| EBIT | 1,136 | 1,073 | -1,102 | -576.4 | -562.9 | -185.1 | -2.47 | 364.3 | 561.2 | - | - | - | - | - |
| Operating Margin | 13.65% | 11.81% | -16.01% | -7.99% | -7.09% | -2.14% | -0.03% | 4.06% | 6.49% | - | - | - | - | - |
| Earnings before Tax (EBT) | 728.5 | 758.9 | -2,246 | -1,514 | -1,069 | -588.8 | -1,070 | 67.66 | 654.4 | - | - | - | - | - |
| Net income | 378.5 | 460.9 | -2,052 | -1,626 | -1,217 | 292.2 | -1,359 | 228.2 | -800.3 | - | - | - | - | - |
| Net margin | 4.55% | 5.07% | -29.81% | -22.53% | -15.32% | 3.37% | -14.46% | 2.54% | -9.25% | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/4/21 | 5/27/21 | 8/6/21 | 11/10/21 | 2/10/22 | 5/24/22 | 7/29/22 | 11/14/22 | 1/24/23 | 5/25/23 | 8/2/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | 22,635 | 14,766 | 16,272 | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 4.977 x | 2.761 x | 2.596 x | - | - | - | - | - |
| Free Cash Flow 1 | -2,690 | 548 | 1,840 | -4,012 | -505 | 5,503 | 7,262 | 9,000 |
| ROE (net income / shareholders' equity) | 12.7% | 1.41% | 10.1% | -17.9% | -8.9% | 4.95% | 12% | 15.3% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 296.0 | 282.0 | 292.0 | 263.0 | 241.0 | 242.0 | 272.0 | 305.0 |
| Cash Flow per Share | 49.00 | 64.30 | 72.80 | - | - | - | - | - |
| Capex 1 | 3,291 | 1,500 | 2,975 | 1,434 | 949 | 2,000 | 1,280 | 1,607 |
| Capex / Sales | 10.93% | 5.45% | 8.97% | 4.67% | 2.57% | 4.86% | 2.84% | 3.24% |
| Announcement Date | 5/10/19 | 5/20/20 | 5/27/21 | 5/24/22 | 5/25/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
876.7
INR
Average target price
830.5
INR
Spread / Average Target
-5.27%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +35.03% | 966M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- STAR Stock
- Financials Strides Pharma Science Limited
